Second positive Phase III trial of AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results